Novel molecular-targeted therapeutics for the treatment of cancer.
Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in cancer, particularly the receptor tyrosine kinases, the intracellular pathways, and the genetic and epigenetic alterations, resulting in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of solid tumors as well as hematologic malignancies. Many of these are novel, targeted agents that have demonstrated significant efficacy and prolonged survival. Here, we discuss the current understanding of the mechanisms of action of novel molecular targeted cancer therapies being tested in the preclinical and clinical settings, including agents that act directly on the cell surface receptors, intracellular signaling pathways, and cell maintenance processes.
First Department of Internal Medicine, Sapporo Medical University, South 1, West 17, Chuo-ku, Sapporo, 060-0061, Japan.
Hiroshi
H
Yasui
Kohzoh
K
Imai
D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases